Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $29.50 Average Price Target from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received a consensus rating of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $29.50.

Several equities analysts have issued reports on CPRX shares. HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Citigroup lifted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 9th.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $19.56 on Monday. The firm’s 50-day simple moving average is $19.22 and its two-hundred day simple moving average is $16.95. Catalyst Pharmaceuticals has a fifty-two week low of $11.55 and a fifty-two week high of $21.67. The stock has a market cap of $2.31 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 3.27 and a beta of 0.75.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. The business had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. Equities research analysts predict that Catalyst Pharmaceuticals will post 1.82 EPS for the current year.

Insider Activity at Catalyst Pharmaceuticals

In related news, Director David S. Tierney sold 15,000 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total value of $3,052,500.00. Following the completion of the sale, the insider now owns 675,124 shares of the company’s stock, valued at $13,738,773.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,058 shares of company stock valued at $4,018,188. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Catalyst Pharmaceuticals in the second quarter valued at $153,000. PVG Asset Management Corp bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at about $183,000. Point72 Asset Management L.P. raised its stake in shares of Catalyst Pharmaceuticals by 47.9% during the second quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company’s stock valued at $9,577,000 after purchasing an additional 200,370 shares in the last quarter. Quarry LP lifted its holdings in Catalyst Pharmaceuticals by 170.0% in the second quarter. Quarry LP now owns 16,334 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 10,284 shares during the period. Finally, Algert Global LLC bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at about $165,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.